I now wonder whether Hikma and RDY have chosen to absent themselves with their respective IPE products from some or all U.S. pharmacy formularies. Also wonder whether FDA/OCI have started an investigation or finished, and 2 generics now have no label/IPE product with which to compete with Amarin in U.S. Will try to call this afternoon or tomorrow to ask a few questions.
Market Data 
Markets 
AI
